A pivotal retatrutide clinical trial has officially crossed a major milestone. The study formally titled A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease — registered on ClinicalTrials.gov as NCT05882045 — has completed, with a primary completion date of April 16, 2026. This marks a significant step forward in the development of retatrutide, the investigational triple agonist that has generated extraordinary interest across the obesity medicine community.
This TRIUMPH-series trial enrolled adults living with obesity who also carry a diagnosis of established cardiovascular disease — a population with some of the highest medical urgency for effective, durable weight loss interventions. Cardiovascular disease and obesity exist in a dangerous bidirectional relationship: excess adiposity worsens cardiac outcomes, while cardiovascular risk compounds the harms of ongoing obesity. Finding a pharmacologic treatment that addresses both simultaneously has been a long-standing goal in the field.
Retatrutide works by simultaneously activating three hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This triple agonist mechanism — sometimes called "triple G" in patient communities — distinguishes it from currently approved therapies. GLP-1 receptor activation reduces appetite and slows gastric emptying. GIP receptor activation enhances metabolic efficiency and may improve tolerability. Glucagon receptor activation increases energy expenditure. Together, these actions produce weight loss outcomes that, based on Phase 2 and Phase 3 data, appear to exceed anything previously observed in a pharmacologic obesity trial.
While peer-reviewed results from this specific cardiovascular cohort are not yet published, the broader retatrutide Phase 3 TRIUMPH-4 trial — also completed — reported a mean weight loss of 28.7% at the 12mg dose over 68 weeks. This is the highest mean weight loss ever recorded in a Phase 3 obesity clinical trial. To put that figure in clinical context, the table below compares retatrutide's Phase 3 performance against other landmark obesity pharmacotherapy trials:
| Medication | Trial | Duration | Mean Weight Loss (Highest Dose) |
|---|---|---|---|
| Semaglutide 2.4mg | STEP-1 | 68 weeks | ~14.9% |
| Tirzepatide 15mg | SURMOUNT-1 | 72 weeks | ~20.9% |
| Retatrutide 12mg | TRIUMPH-4 | 68 weeks | 28.7% |
Earlier Phase 2 retatrutide data, published in the New England Journal of Medicine in 2023 (Jastreboff et al., NCT04881760), had already suggested this trajectory. At 48 weeks, participants receiving the 8mg dose experienced a mean weight loss of approximately 22.8%, with 100% of participants in that group achieving at least 5% weight loss. At the 12mg dose, mean weight loss reached 24.2%, with 48% of participants losing 25% or more of their body weight. These figures were remarkable at Phase 2 and have only been reinforced by Phase 3.
Beyond the scale, Phase 2 data demonstrated meaningful improvements in cardiometabolic markers. Fasting triglycerides fell by 34.0% in the 12mg group at 24 weeks, compared to just 3.1% with placebo. Total cholesterol declined by 17.3% at the 12mg dose, and LDL cholesterol dropped by 15.6–16.9% in the 8mg groups. These lipid improvements are clinically relevant for a drug now being studied specifically in patients with cardiovascular disease.
The drug's tolerability profile warrants honest discussion. The most common adverse events in Phase 2 were gastrointestinal — nausea, diarrhea, and vomiting — consistent with the GLP-1 mechanism and most prominent during dose titration. In the TRIUMPH-4 Phase 3 data, dysesthesia (abnormal skin sensations) occurred in 20.9% of participants at the 12mg dose versus 0.7% with placebo, a signal that requires further characterization. Discontinuation rates at the 12mg dose were 18.2%, compared to 4.0% in the placebo group. Notably, some participants discontinued due to what was described as perceived excessive weight loss — an observation without precedent in prior obesity pharmacotherapy trials.
Retatrutide, commonly referred to as reta in patient communities, has become one of the most anticipated medications in recent obesity medicine history. Many patients describe their struggles with obesity as driven in part by persistent "food noise" — the intrusive, constant preoccupation with food that makes behavioral interventions alone feel insufficient. The triple agonist mechanism of retatrutide appears to address food noise through its GLP-1 component while simultaneously driving metabolic change through the glucagon pathway.
Trial completion is a necessary — but not final — step on the path to FDA approval. When a Phase 3 study completes, the sponsor (in this case, Eli Lilly and Company) must compile a comprehensive data package across all relevant trials, including efficacy, safety, tolerability, and manufacturing data, and submit a New Drug Application (NDA) to the FDA.
As of April 2026, Eli Lilly has not yet filed an NDA for retatrutide, and the FDA approval timeline has not been publicly confirmed. Peer-reviewed Phase 3 publications are also pending as of this writing. The completion of this cardiovascular outcomes study adds a critical piece of safety and efficacy evidence that will likely be included in a future regulatory submission — and its completion signals that the full data package may be approaching readiness.
The FDA's standard review timeline for priority review designations runs approximately six months from NDA submission; standard review takes closer to ten to twelve months. Whether retatrutide receives a priority designation — typically granted when a drug offers a significant improvement over available therapies — remains to be seen, though its efficacy profile would appear to support such a designation.
Predicting FDA approval timelines with precision is not possible, particularly before an NDA is filed. What can be said with confidence is that the data landscape for retatrutide is advancing rapidly. The completion of multiple TRIUMPH-series trials, including this cardiovascular cohort, moves the regulatory timeline forward in a meaningful way.
Patients who are candidates for advanced obesity pharmacotherapy — those with a BMI of 30 or higher, or 27 or higher with a weight-related comorbidity such as hypertension or dyslipidemia — are the population most likely to benefit from retatrutide if and when it is approved. The Phase 2 trial specifically excluded individuals with type 2 diabetes, though separate trials in that population are ongoing.
The cardiometabolic benefits observed in the lipid and inflammatory marker data, combined with Phase 3 weight loss outcomes that surpass all prior pharmacologic benchmarks, suggest that retatrutide — if approved — could represent a meaningful advance in the treatment of obesity as a chronic disease.
For patients and clinicians who want to stay ahead of retatrutide's development, glp3md.com maintains an active waitlist and regularly publishes clinical updates as peer-reviewed data becomes available. Joining the waitlist means receiving accurate, timely information about trial results, regulatory milestones, and availability updates as they are confirmed. Please note: joining the waitlist does not guarantee access to retatrutide, a prescription, or any form of treatment. Retatrutide is not FDA-approved, and no promises regarding medication availability can or should be made. Visit glp3md.com to add your name and stay informed as this story continues to unfold.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.